clinical trial · NCT00650520
Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
HealthyBROMOCRIPTINE MESYLATE CAPSULES, USP 5 mgParlodel® (bromocriptine mesylate) capsules, USP 5 mg
brief summary
The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed conditions.
started
May 1, 2007
primary completion
Jul 1, 2007
completion
Jul 1, 2007
last updated
Apr 24, 2024
official title
Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol